Login to Your Account

Financings Roundup

'Regado' Nuff Money Now? IPO Brings $43M to Push Phase III

By Randy Osborne
Staff Writer

Friday, August 23, 2013
Regado Biosciences Inc.'s initial public offering (IPO) may not have made quite the splash that others have made in recent months, but the sale of about 10.7 million shares at $4 each provided $43 million that will help the firm's REG1, on the runway for Phase III trials, move ahead in percutaneous coronary intervention for acute coronary syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription